Rapid Implementation of Novel Affinity Purification 

The rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based candidates with modified or absent Fc domains increases, biomanufacturers face a need to establish alternative affinity purification technologies.

Download this whitepaper to discover affinity resins that:

• Provide a scalable platform solution for efficient therapeutic antibody purification 
• Can be used in commercial manufacturing processes of antibody therapeutics
• Provide increased capacity and high purity of novel antibody formats in a single capture step